- Love and Other Tragedies Slated for Release featuring Cure's Roger O'Donnell
- Harless Hall of Fame to welcome three new members in ceremony May 7
- McConaughey Tweets "Long Way from 1971..."
- BOOK REVIEW: 'Suspicion': Delightfully Scary Novel Aimed at Young Women Hits Its Target Like an Arrow from Robin Hood
- Fixing Slips Forced Priority for Huntington, Mayor Says
- A Dad’s Point-of-View: It’s Not Prostitution; It’s Just an Arrangement
- OP-ED: How Prosecutors Think
- Southern Faces Federal Criminal Charges for Bankruptcy and Wire Fraud in January MCHM Spill
- Huntington Police Arrest Suspect in Car Vandalism
- Huntington Water Quality Board Meets Jan. 13 at 11 a.m.
Biomedical sciences researcher to present results of clinical trials on personalized chemotherapy
Thursday, June 12, 2014 - 03:21 Updated 46 weeks ago Special to HNN Provided by Marshall University
He will be discussing the results of clinical trials conducted at the Edwards Comprehensive Cancer Center. The studies tested ChemoID, a cell culture method he developed with colleague Dr. Jagan Valluri to measure the sensitivity of patients' tumors to chemotherapy treatment for lung, brain/spine and breast cancer.
He says more evaluation of the technology is needed, but preliminary tests on a small number of patients found ChemoID 100 percent accurate in predicting which drug is more effective in treating patients affected by brain cancer if the tumor-initiating cancer stem cells were evaluated.
"Oncologists every day face many challenges in determining the best course of therapy for an individual cancer patient," says Claudio. "The basic problem is that patients with similar diagnoses don't always respond to the same chemotherapy. This technology we have developed could help physicians select the appropriate chemotherapy for an individual patient giving them an edge in the fight against cancer."
He says the good news for cancer patients is that ChemoID may make possible personalized treatment by predicting the most effective drug combination to successfully target that specific patient's cancer increasing the chance the drugs will work and perhaps reducing side effects by helping the patient avoid unnecessary drugs.
In addition to presenting his own research at the conference, Claudio will be moderating a session, "Advances in Oncology and Anticancer Research. Cancer Pathology."
Summaries of the research presented at the meeting will be published in the journal Frontiers in Bioscience.